Clinical trials: Cancer Stem Cells
Acute Myeloid Leukemia, MDS
ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS
ClAraC (consisting of one dose of clofarabine and ara-C for five days) or FLAMSA (consisting of one dose of fudarabine, amsacrine and ara-C for four days) will be administered followed by reduced-intensity conditioning regimen…
- Trial name
- ClAraC-SCT (NCT01423175)
- Testing
- Clofarabine, ara-C, FLAMSA
- Where
- 3 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Hannover Medical School
Precursor Lymphoid Neoplasms
Personalized Therapy of Precursor Lymphoid Neoplasms
The primary goal of this study by The Polish Adult Leukemia Group (PALG) is to verify if individual therapeutic approach taking into account biological and phenotypic differences as well as response at the level of minimal…
- Trial name
- NCT01665001
- Testing
- Treatment strategy: induction, consolidation, HSCT, maintenance
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
The purpose of the study is to compare safety and efficacy of stem cell mobilization using G-CSF (filgrastim) alone vs. intermediate-dose cytosine arabinoside plus G-CSF in Hodgkin's lymphoma and non-Hodgkin's lymphoma patients.
- Trial name
- NCT02722733
- Testing
- G-CSF (filgrastim), Cytosine arabinoside with G-CSF (filgrastim)
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Central Nervous System Infections, Central Nervous System Complication
Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation
All patients undergoing allogeneic or autologous HSCT at the participating centres will be observed. Once a diagnosis of CNS disorder is made, additional data will be reported for these patients.
- Conditions
- Central Nervous System Infections, Central Nervous System Complication, Infectious Disease of Nervous System, Blood Disease
- Trial name
- NCT04737785
- Where
- 22 sites in Australia, Colombia and 10 more
- Volunteers
- 252 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Newly Diagnosed Myeloma Patient Above 65 Years Old
Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years
Autologous stem cell transplantation remains the gold standard of treatment for newly diagnosed patients under the age of 65. Even though it is also regularly performed above the age of 65, there are very few data in this patient…
- Trial name
- LATMM (NCT01671826)
- Where
- 6 sites in France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma and Plasma Cell Neoplasm
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602706
- Testing
- sargramostim, melphalan, autologous hematopoietic stem cell transplantation
- Volunteers
- 76 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
The purpose of this trial is to confirm the safety and efficacy of high-dose Melphalan HCL for Injection (Propylene Glycol-Free) as a myeloablative conditioning regimen in multiple myeloma patients (MM) undergoing autologous…
- Trial name
- NCT01660633
- Testing
- High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
- Where
- 6 sites in United States
- Volunteers
- 61 people
- Sponsor
- Acrotech Biopharma Inc.
Multiple Myeloma
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant approach in newly diagnose myeloma patients younger than 65 years
- Trial name
- NCT00702247
- Testing
- Hematopoietic Stem Cell Transplantation
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Plasma Cell Myeloma
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant.
- Trial name
- NCT04876248
- Testing
- Belantamab Mafodotin, Lenalidomide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Hematologic Diseases, Neoplasms
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant…
- Trial name
- NCT05827835
- Testing
- CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Gliomas
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
The primary objective of this study is to evaluate the efficacy of a combined treatment with cilengitide and metronomic oral temozolomide as measured by 6 months overall survival (OS) after diagnosis of relapse or tumour…
- Trial name
- HGG-CilMetro (NCT01517776)
- Testing
- Cilengitide, Temozolomide
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Glioma
Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG).
- Trial name
- PBTC-047 (NCT02717455)
- Testing
- LBH589
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pediatric Brain Tumor Consortium
Fatigue, Leukemia
Effects of Periodized and Autoregulated Resistance Training in Haematological Cancer Patients During the Treatent.
Several clinical trials have demonstrated the positive impact of physical functioning and fatigue in patients who received training programs during the myeloablative chemotherapy with stem cell transplantation.
- Conditions
- Fatigue, Leukemia, Lymphoma, Physical Disability
- Trial name
- NCT04406285
- Testing
- Standard protocol Leukemia, Periodic Resistance Training Program Leukemia, Standard protocol Lymphoma
- Where
- 2 sites in Brazil
- Volunteers
- 66 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Childhood Cancer
Cardiopulmonary Fitness and Its Clinical Determinants of a Population of Childhood Cancer Survivor
Medical progress have made it possible to considerably improve the survival of children with an oncological disease. Currently, the survival rate increased to above 90 % in the most developed countries .
- Trial name
- ONCO-SPORT (NCT04815447)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Montpellier
Febrile Neutropenia
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
This randomised controlled trial will determine the non-inferiority of stopping empiric antibiotics prior to absolute neutrophil count (ANC) recovery (Early Stopping) versus stopping antibiotics upon ANC recovery (Standard of…
- Trial name
- ELSA-FN (NCT04948463)
- Testing
- Piperacillin and Tazobactam for Injection, Cefepime Injection, Ceftazidime Injection
- Where
- Australia
- Volunteers
- 55 people
- Sponsor
- Murdoch Childrens Research Institute
Mantle Cell Lymphoma
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose…
- Trial name
- NCT01170052
- Testing
- Temsirolimus, Bendamustine
- Where
- 3 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Graft Versus Host Disease, Leukemia
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myeloma
- Trial name
- ProT4 (NCT01240525)
- Testing
- CD4 DLI, No DLI
- Where
- 11 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- University College, London
Acute Myeloid Leukaemia
Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation
A phase 1 study of infusion of partially HLA matched unrelated donor blood or marrow cells (microtransplantation) following consolidation chemotherapy in patients with AML that are not suitable for allogenic stem cell…
- Trial name
- SCRAMBLE (NCT02189824)
- Testing
- Partially HLA-matched unrelated donor cells
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- University of Sydney
Lymphoma
Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00005824
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- AIDS Malignancy Consortium
Multiple Myeloma
Exploratory Study on POL6326 in Stem Cell Mobilization
The purpose of this study is to determine whether POL6326 is safe and clinically active to mobilize hematopoietic stem cells followed by transplantation
- Trial name
- NCT01105403
- Testing
- POL6326
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Polyphor Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.